Hemant Surgical Industries Ltd543916Corporate

Medical Equipment & Supplies Latest results: Mar 2026 3 quarters of data

₹418.10

MCap ₹544 Cr

Hemant Surgical Industries Ltd — Stock analysis & AI research Hemant Surgical Industries Ltd — Live exchange announcements

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹167 Cr

Sales · Mar 2026

+187.9% YoY

₹16 Cr

Operating Profit · Mar 2026

+220.0% YoY

9.6%

OPM % · Mar 2026

+11.6% YoY

₹13 Cr

Net Profit · Mar 2026

+160.0% YoY

₹9.76

EPS · Mar 2026

+109.4% YoY

📝 Hemant Surgical Industries Ltd — results explained

Quarter ended March 2026 (Q4 FY26)

Hemant Surgical Industries Ltd reported revenue of ₹167 crore for the quarter ended March 2026 (Q4 FY26), up 187.9% from ₹58 crore in the same quarter last year.

Net profit rose 160.0% year-on-year to ₹13 crore, from ₹5 crore. Earnings per share (EPS) came in at ₹9.76.

Operating profit stood at ₹16 crore — an operating margin (OPM) of 9.6%, compared with 8.6% in the year-ago quarter.

Valuation snapshot

At the current price of ₹418.10, 543916 has a market capitalisation of ₹544 crore.

Within the Medical Equipment & Supplies industry, it is the 4th-largest of the 13 companies we track by market value.

Shareholding pattern

As of May 2026, promoters held 52.83%, foreign institutional investors (FIIs) 0.14%, domestic institutional investors (DIIs) 19.94%, public shareholders 27.10% of Hemant Surgical Industries Ltd.

Promoter holding slipped from 58.90% to 52.83% over the latest period.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹544 Cr

Current Price ?

₹418.1

P/E ?

N/A

Industry P/E ?

26.90

P/B ?

3.94

P/S ?

N/A

P/FCF ?

-15.99

Enterprise Value ?

₹594 Cr

EV/EBITDA ?

N/A

PEG ?

N/A

Earnings Yield ?

N/A

Dividend Yield ?

0.00%

Profitability & Returns

Sales (TTM) ?

N/A

OPM ?

N/A

Profit after tax (TTM) ?

N/A

EPS (TTM) ?

N/A

ROCE ?

20.0%

ROE ?

N/A

ROA ?

N/A

Growth

Sales — latest qtr ?

₹167 Cr

PAT — latest qtr ?

₹13 Cr

YoY qtr sales growth ?

187.9%

YoY qtr profit growth ?

160.0%

Sales growth (3y) ?

N/A

Sales growth (5y) ?

N/A

Profit growth (3y) ?

N/A

Profit growth (5y) ?

N/A

Financial Health

Debt ?

₹50 Cr

Debt to Equity ?

0.36

Interest Coverage ?

N/A

Current Ratio ?

N/A

Ownership

Promoter holding ?

52.83%

Change in promoter holding ?

-20.73%

Pledged percentage ?

N/A

Market

Return 3 months ?

11.4%

Return 6 months ?

53.9%

🗓️ Quarterly results (3 quarters · ₹ Cr)

same fiscal quarter as Mar bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Mar 2025	Sep 2025	Mar 2026	YoY %	QoQ %
Sales	58	65	167	+187.9%	—
Operating Profit	5	8	16	+220.0%	—
Other Income	3	2	4	+33.3%	—
Interest	1	2	2	+100.0%	—
Depreciation	1	1	1	+0.0%	—
Profit Before Tax	6	7	16	+166.7%	—
Net Profit	5	5	13	+160.0%	—
EPS	4.66	4.19	9.76	+109.4%	—
OPM %	8.6%	12.3%	9.6%	+11.6%	—

📆 Annual results (₹ Cr, FY = Apr–Mar)

Annual rollup not yet available We need at least 3 quarters of a fiscal year to compute annual figures. This symbol does not yet have a complete fiscal year in our database.

🏛️ Balance Sheet (latest 2 periods)

Metric	Mar 2025	Mar 2026	% Chg
Equity Capital	10	13	+30.0%
Reserves	53	125	+135.8%
Borrowings	31	50	+61.3%
Other Liabilities	54	87	+61.1%
Total Liabilities	148	274	+85.1%
Fixed Assets	40	53	+32.5%
CWIP	12	0	-100.0%
Investments	1	0	-100.0%
Other Assets	95	221	+132.6%
Total Assets	148	274	+85.1%

💧 Cash Flow (latest 2 periods)

Metric	Mar 2025	Mar 2026	% Chg
Cash from Operating Activity	9	-32	-455.6%
Cash from Investing Activity	-30	-3	+90.0%
Cash from Financing Activity	18	69	+283.3%
Net Cash Flow	-4	34	+950.0%
Free Cash Flow	-26	-34	-30.8%
CFO/OP	118%	-119%	-200.8%

➗ Ratios (latest 2 periods)

Metric	Mar 2025	Mar 2026	% Chg
Debtor Days	70	106	+51.4%
Inventory Days	208	121	-41.8%
Days Payable	188	146	-22.3%
Cash Conversion Cycle	90	81	-10.0%
Working Capital Days	62	24	-61.3%
ROCE %	—	20%	—

👥 Shareholding (latest 4 periods)

Metric	Mar 2025	Sep 2025	Mar 2026	May 2026	% Chg
Promoters	73.56%	58.90%	58.90%	52.83%	-10.3%
FIIs	0.39%	0.15%	0.15%	0.14%	-6.7%
DIIs	1.11%	10.81%	10.73%	19.94%	+85.8%
Public	24.93%	30.13%	30.21%	27.10%	-10.3%
No. of Shareholders	1,229	758	841	948	+12.7%

⚖️ Peer comparison

Industry: Medical Equipment & Supplies · 13 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	FISCHER Fischer Medical	₹33.50	2,293	85.2	367	24	12.3%	6.7%	178.6%	2051.4%	249.4%	-24.3%
2	TARSONS Tarsons Products	₹330.00	1,756	157.9	441	11	27.0%	2.5%	-66.3%	-81.4%	20.7%	-181.0%
3	DENTALKART Vasa Denticity	₹563.10	977	80.0	299	12	4.4%	4.0%	16.7%	-28.5%	12.9%	-2.9%
4	543916 Hemant Surgical	₹193.85	544	13.9	231	18	10.4%	7.8%	—	—	187.9%	160.0%
5	543363 Prevest Denpro	₹616.50	456	32.8	75	23	35.7%	29.9%	13.6%	17.6%	23.7%	24.8%
6	QMSMEDI QMS Medical	₹185.89	359	52.7	162	7	13.1%	4.1%	5.1%	-47.9%	23.7%	-0.8%
7	NURECA Nureca	₹331.55	331	75.9	153	4	2.7%	2.8%	34.0%	146.7%	18.0%	277.2%
8	530427 Choksi Asia	₹65.64	122	7.2	47	5	14.5%	11.1%	61.1%	173.2%	-22.5%	-10.1%
9	527005 Shree Pacetronix	₹168.25	55	19.2	21	3	24.8%	15.3%	28.7%	324.3%	-8.3%	14.5%
10	544143 Royal Sense	₹139.00	47	24.7	38	3	12.8%	8.0%	—	—	2.5%	-5.4%
11	533212 GKB Ophthalmics	₹104.90	32	17.6	150	6	7.0%	3.7%	36.8%	142.7%	2.3%	388.5%
12	531380 Centenial Surgical	₹110.90	27	—	56	-1	10.7%	-2.6%	0.6%	-38.1%	18.6%	1937.8%
13	542765 Transpact Enterprises	₹325.00	4	140.1	0	0	63.2%	47.4%	—	—	12.5%	-20.0%

❓ Frequently asked questions

What was Hemant Surgical Industries Ltd's revenue in Q4 FY26?